Inhalon Biopharma

Inhalon Biopharma is pioneering a novel inhaled antibody platform that leverages 'muco-trapping' technology to treat acute respiratory infections directly in the lung. Founded in 2016 and based in San Diego, the private company has advanced its lead candidate, IN-006 for COVID-19, into Phase 1b studies and secured significant non-dilutive grant funding from U.S. government agencies. With a focus on enabling at-home, test-to-treat models, Inhalon aims to address a major unmet need in respiratory care by developing fast-acting, locally delivered therapeutics.

Muco-trapping antibody platform: Engineered inhaled antibodies that trap pathogens (viruses, bacteria, fungi) in airway mucus by crosslinking them to mucins, enabling rapid clearance via natural mucociliary mechanisms.

Inhalon competes with large pharmaceutical companies developing oral antivirals (e.g., Pfizer's Paxlovid) and systemic antibodies, as well as other biotechs exploring inhaled therapeutics. Its differentiation hinges on the unique muco-trapping mechanism and the potential for superior local efficacy with at-home convenience.